Developed and used clinically in Russia for cognitive and cerebrovascular indications; not approved by FDA/EMA and lacking large Western trials.
Semax is a short peptide derived from a fragment of the hormone ACTH, but engineered to remove ACTH's hormonal (stress-axis) activity while keeping effects on the brain. It was developed in Russia.
Its proposed mechanism is to raise brain growth factors like BDNF and NGF and to modulate the brain's monoamine systems — the rationale for its use as a neuroprotective and cognitive ('nootropic') agent in cognitive and stroke contexts.
The important caveat is that its clinical evidence is mostly Russian, small, and not replicated in large rigorous Western trials. It is not approved by the FDA or EMA, so its reputation outpaces its proven evidence.
Searching the published record…
Searching the published record…
Searching the published record…
No indexed in vitro studies found for this term. Try the live PubMed query below.
Search this category on PubMed →Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.